The effectiveness of nano‐curcumin on patients with COVID‐19: A systematic review of clinical trials

Abstract

The main aim of the current study was to summarize the findings of available clinical studies to assess nano‐curcumin's influence on COVID patients. A comprehensive online search was performed in Scopus, PubMed, ISI Web of Science, and Google Scholar until March 2022 to identify trials that investigated the effects of nano‐curcumin in patients with COVID‐19. Eight studies comprising 569 patients were included in this review. Compared with placebo, nano‐curcumin had no significant effect on C‐reactive protein (CRP) and high‐sensitivity C‐reactive protein (hs‐CRP), tumor necrosis factor‐α (TNF‐α), and interleukin‐6 (IL‐6). However, gene expression of IL‐6 and gene expression as well as secretion of interleukin‐1 beta (IL‐1β) significantly decreased following nano‐curcumin intervention. Nano‐curcumin had beneficial effects on fever, cough, chills, myalgia, and olfactory and taste disturbances. The duration of hospitalization and mortality rate were significantly lower in the nano‐curcumin group compared with the control group. Lymphocyte count was significantly increased after curcumin supplementation. Nano‐curcumin also had favorable effects on O2 saturation, sputum, chest pain, wheeze, and dyspnea in patients with COVID‐19. No major adverse effects were reported in response to nano‐curcumin supplementation. In summary, the results of this systematic review of clinical trials suggested that nano‐curcumin supplementation has beneficial effects on inflammation, respiratory function, disease manifestations, and complications in patients with COVID‐19 viral infection.

Adjunctive nano‐curcumin therapy improves inflammatory and clinical indices in children with cystic fibrosis: A randomized clinical trial

“…Moreover, in patients undergoing angioplasty, nano‐curcumin at the same dose caused a significant decrease in hs‐CRP levels (Helli et al, 2021 ).Besides, the systematic review had shown that curcumin improved the severity of inflammation including asthma, inflammatory bowel disease, and juvenile idiopathic arthritis (Heidari et al, 2022 ). By using nano‐curcumin in COVID‐19 patients, although it did not have a significant effect on CRP, hs‐CRP, and IL‐6, it decreased the gene expression of IL‐6 (Shojaei, Foshati, et al, 2023 ).…”

Developments and Trends of Nanotechnology Application in Sepsis: A Comprehensive Review Based on Knowledge Visualization Analysis

“…In response, recent years have seen the development of nanocarriers that deliver plant-derived antioxidants. An example is nanocurcumin, synthesized from nanomaterials, which has shown promise in clinical trials for effectively alleviating cytokine storms in sepsis patients. , This approach represents a significant stride in sepsis management, leveraging the natural antioxidant properties of plant-based compounds in a nanomedicine format. These developments in antioxidant nanoplatforms offer a more logical, concise, and academically rigorous perspective on combating the detrimental effects of ROS in sepsis, indicating a promising direction for future research and therapeutic applications.…”

Cell Survival, Death, and Proliferation in Senescent and Cancer Cells: the Role of (Poly)phenols

“…Observations on curcumin kinetics reveal markedly low serum levels, rapid metabolism with the formation of inactive metabolites, limited tissue distribution, and rapid clearance/elimination from the body [ 114 ]. However, different biological activities of curcumin have been reported in human studies [ [120] , [121] , [122] , [123] ]. The current debate to untangle the ambiguity between the bioavailability and biological activity of curcumin also seems to reside on curcumin’s bidirectional interaction with gut microbiota and an individual’s metabolic capacity, which depends on microbiota biodiversity [ 124 ].…”